Skip to main content
TipRanks
Go Ultimate75% OFF

Telix Pharmaceuticals (TLX) Drug Pipeline

654 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
89Zr-Dfosq-OlaratumabSoft Tissue Sarcoma, Pdgfr Alpha Positive Solid TumoursPhase IRecruiting89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue SarcomaApr 29, 2024―
Standard Of Care, 177Lu-Dota-RosopatambMetastatic Prostate CancerPhase IIITerminatedThe Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care OnlyMay 03, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Telix Pharmaceuticals Ltd. (AU:TLX) have in its pipeline
Telix Pharmaceuticals AU:TLX is currently developing the following drugs: 89Zr-Dfosq-Olaratumab, Standard Of Care, 177Lu-Dota-Rosopatamb. These drug candidates are in various stages of clinical development as the company works toward FDA approval.